Dechra Pharmaceuticals 2018 final results
Strong financial performance:
Revenue growth of 13.9% to £407.1 million.
Underlying operating profit growth of 24.0% to £99.2 million.
Underlying EBIT margin expansion of 200 bps to 24.4%.
Underlying diluted EPS increased by 20.9% to 76.45 pence.
Full year dividend of 25.50 pence, up 18.9%.
